Tick-Borne Antibodies, Modified 2-Tier, ELISA, Serum
Use
This test provides evaluation of the most common tick-borne diseases found in the United States, including Lyme disease, human monocytic and granulocytic ehrlichiosis, and babesiosis. It uses a modified 2-tier testing approach to detect antibodies associated with these infections. The test can assist in the diagnosis of Lyme disease, and is useful for patients presenting with fever, myalgia, headache, nausea, and other nonspecific symptoms related to tick exposure. The panel is also suitable for sero-epidemiological surveys of infection prevalence in specific populations.
Special Instructions
Not provided.
Limitations
Serological tests may be nonreactive during acute phases of infections. PCR testing is recommended for early detection of Anaplasma phagocytophilum or Ehrlichia chaffeensis. Detectable IgG-class antibodies usually appear 7-10 days post-symptom onset and may persist for months to years. A negative result does not exclude the possibility of Lyme disease infection, especially in early stages or in antibiotic-treated patients. Positive results for Lyme disease require further confirmation to rule out potential cross-reactivity with other conditions.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 103603-7 - STICK Ser
- 23877-4 - A phagocytoph IgG Titr Ser IF
- 16117-4 - B microti IgG Titr Ser
- 47405-6 - E chaffeensis IgG Titr Ser IF
- 83081-0 - B burgdor IgG+IgM Ser Ql IA
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.35 mL
Minimum Volume
1.1 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial. Preferred collection container is Serum gel or alternatively, a Red top tube.
Causes for Rejection
Gross hemolysis, lipemia, and icterus, or heat-inactivated specimens are rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 10 days |
| Frozen | 14 days |